SAN DIEGO, April 22, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) announced today that the company’s TransVax™ cytomegalovirus (CMV) vaccine elicited sustained increases in both cellular and antibody immune responses compared with placebo through the final 12-month follow-up in an ongoing Phase 2 trial in hematopoietic cell transplant (HCT) recipients. Richard T. Kenney, M.D., Vical’s Vice President of Clinical Development, is presenting the encouraging preliminary data today at the World Vaccine Congress (Washington – April 19-22).
